Identifying
ongoing hemolysis
Despite normalization across some key measures, hemolysis may persist1
with PNH currently on C5 inhibition.
35 years old*
35 years old*
47 years old*
47 years old*
patient profiles are based on the
following sources: Schrezenmeier
Haematologica 2014, Risitano Front
Immunol 2019, Risitano Blood 2009,
Young Semin Hematol 2009,
and McKinley Blood 2017.
patient profiles are based on the
following sources: Schrezenmeier
Haematologica 2014, Risitano Front
Immunol 2019, Risitano Blood 2009,
Young Semin Hematol 2009,
and McKinley Blood 2017.
of Hb
Hemoglobin is the most direct indicator of clinical severity in hemolytic diseases. Hemoglobin levels are pivotal for treatment response evaluation4
In hemolytic conditions, LDH is often increased, and may be useful in distinguishing between EVH and IVH (can be slightly increased in EVH and multiple-fold greater than the ULN in IVH)4
Reticulocyte count is an indicator of bone marrow function and levels are usually increased in hemolysis4
of bilirubin
Elevated bilirubin levels can be caused by increased hemoglobin breakdown in the liver and spleen4
patients who struggle with unresolved symptoms may need more from treatment1
ARC=absolute reticulocyte count; EVH=extravascular hemolysis; Hb=hemoglobin; IVH=intravascular hemolysis; LDH=lactate dehydrogenase; PNH=paroxysmal nocturnal hemoglobinuria; QoL=quality of life; RBC=red blood cell; ULN=upper limit of normal.
References: 1. Risitano AM, et al. Front Immunol. 2019;10:1157. 2. Schrezenmeier H, et al. Haematologica. 2014;99(5):922-929. 3. Young N, et al. Semin Hematol. 2009;46(1 suppl 1):S1-S16. 4. Barcellini W, et al. Dis Markers. 2015;2015:1-7. 5. Risitano AM, et al. Blood. 2009;113(17):4094-4100. 6. Ueda Y, et al. Int J Hematol. 2018;107(6):656-665. 7. Hill A, et al. Haematologica. 2010;95(4):567-573. 8. Brodsky RA. Blood. 2014;124(18):2804-2811. 9. Lee JW, et al. Am J Hematol. 2019;94:S1-S2. 10. Lee JW, et al. Am J Hematol. 2019;94(1):E37-E41.